Hamman-Rich syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 14: | Line 14: | ||
***[[Gastrointestinal bleeding]] | ***[[Gastrointestinal bleeding]] | ||
*** [[Hospital-acquired pneumonia]] | *** [[Hospital-acquired pneumonia]] | ||
*** Secondary [[pulmonary hypertension]] | |||
*** [[Anemia]] | *** [[Anemia]] | ||
***[[Sepsis]] | ***[[Sepsis]] | ||
*Pulmonary rehabilitation (eg, patient education, optimal exercise program) | *Pulmonary rehabilitation (eg, patient education, optimal exercise program) | ||
*Maintain ideal body-mass index | |||
**Reduction of weight if obese | |||
**Nutritional support if the patient is cachectic | |||
*[[Vaccination]] against possible causes of pulmonary inflammation as [[influenza]] and [[Streptococcus pneumoniae|pneumococca]]<nowiki/>l vaccines.<ref name="pmid25233284">{{cite journal |vauthors=Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T |title=Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP) |journal=MMWR Morb. Mortal. Wkly. Rep. |volume=63 |issue=37 |pages=822–5 |date=September 2014 |pmid=25233284 |pmc=5779453 |doi= |url=}}</ref> | *[[Vaccination]] against possible causes of pulmonary inflammation as [[influenza]] and [[Streptococcus pneumoniae|pneumococca]]<nowiki/>l vaccines.<ref name="pmid25233284">{{cite journal |vauthors=Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T |title=Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP) |journal=MMWR Morb. Mortal. Wkly. Rep. |volume=63 |issue=37 |pages=822–5 |date=September 2014 |pmid=25233284 |pmc=5779453 |doi= |url=}}</ref> | ||
==Medical Therapy== | ==Medical Therapy== | ||
Latest revision as of 17:04, 23 March 2018
|
Hamman-Rich syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hamman-Rich syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Hamman-Rich syndrome medical therapy |
|
Risk calculators and risk factors for Hamman-Rich syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]
Overview
There is no effective treatment for acute interstitial pneumonitis, Management in general includes supportive therapy and administration of glucocorticosteroids and Immunosuppressive agents.
Supportive care
- Patients with acute interstitial pneumonitis receive supportive care alongside the medical therapy[1]:
- Pulmonary rehabilitation (eg, patient education, optimal exercise program)
- Maintain ideal body-mass index
- Reduction of weight if obese
- Nutritional support if the patient is cachectic
- Vaccination against possible causes of pulmonary inflammation as influenza and pneumococcal vaccines.[2]
Medical Therapy
- Corticosteroid therapy:[3]
- Once the diagnosis of acute interstitial pneumonitis is confirmed, high doses of glucocorticosteroids (eg, methylprednisolone) should be administered.
- Monitor the patient for glucocorticosteroid-induced side effects (eg, hyperglycemia, increased susceptibility to infection, gastritis).
- Immunosuppressive therapy
References
- ↑ Suh GY, Kang EH, Chung MP, Lee KS, Han J, Kitaichi M, Kwon OJ (March 2006). "Early intervention can improve clinical outcome of acute interstitial pneumonia". Chest. 129 (3): 753–61. doi:10.1378/chest.129.3.753. PMID 16537878.
- ↑ Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T (September 2014). "Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Morb. Mortal. Wkly. Rep. 63 (37): 822–5. PMC 5779453. PMID 25233284.
- ↑ Avnon LS, Pikovsky O, Sion-Vardy N, Almog Y (January 2009). "Acute interstitial pneumonia-Hamman-Rich syndrome: clinical characteristics and diagnostic and therapeutic considerations". Anesth. Analg. 108 (1): 232–7. doi:10.1213/ane.0b013e318188af7a. PMID 19095855.